With increasing evidence of safety and efficacy in clinical trials, oncolytic viruses offer a ray of hope in fighting against cancers. Live attenuated measles virus (MeV) can be developed for oncolytic use. Creative Biogene has developed Measles Virus (MeV) Platform with the goal of promoting the research progress in cancer treatment by means of oncolytic measles viruses.